SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The S&P 500 is trading lower as investors weigh rising Treasury yields and an industry-wide debate over the pace of artificial intelligence development. Market participants remain cautious and volatile ahead of the upcoming Federal Reserve policy decision.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending as traders react to rising long-term Treasury yields and intensifying debate over a potential Federal Reserve rate hike in September. Investors are focused on the intersection of persistent inflation pressures—exacerbated by rising oil prices—and active policy intervention, including Treasury bond buybacks, with many questioning the ability of these measures to offset the broader upward pressure on yields.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is trending following the official completion of the acquisition of Chain Technology and Services, which integrates significant payments infrastructure into the Onyx ecosystem. While some traders view this as a bullish foundation for a future neobank, others remain skeptical, dismissing the movement as a potential pump-and-dump scheme characterized by ongoing volatility and dilution concerns.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The index is fluctuating as traders react to conflicting signals regarding AI development and potential rate hikes, with market sentiment heavily influenced by uncertainty over AI-related capital expenditure and Federal Reserve policy. Despite early selling pressure, the market has seen aggressive intraday bounces, reflecting a high level of debate over the durability of the AI trade versus macroeconomic risks.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

The conversation is highly fragmented and politically charged, with participants debating the economic impact of the ongoing conflict in Iran, rising fuel prices, and recent reports regarding the financing of the Trump family wedding. Traders are also actively discussing and clashing over recent geopolitical maneuvers, AI regulatory policies, and the political implications of upcoming midterm elections.

Nasdaq, Inc. is a holding company, which engages in trading, clearing, exchange technology, regulatory, securities listing, information, and public and private company services. It operates through the following segments: Capital Access Platforms, Financial Technology, and Market Services. The Capital Access Platforms segment delivers liquidity, transparency, and integrity to the corporate issuer and investment community by empowering clients to effectively navigate the capital markets, achieve their sustainability goals, and drive governance excellence. The Financial Technology segment offers platforms that improve the liquidity, transparency, and integrity of the global economy by architecting and operating the markets. The Market Services segment includes equity derivative trading and clearing, cash equity trading, fixed income, currency, and commodities trading. The company was founded by Gordon S. Macklin in 1971 and is headquartered in New York, NY.

Nasdaq Inc - Ordinary Shares - 144A

Nasdaq Inc

Investors are actively discussing Nasdaq's recent investment in the parent company of the crypto exchange Kraken, which aims to facilitate 24/7 trading of tokenized stocks by 2027. Additionally, the conversation reflects broader market sentiment regarding potential interest rate cuts and general technical analysis trends.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending following a recent initiation of coverage by Rosenblatt, which issued a Buy rating and a bullish price target, highlighting the company's positioning as a key player in AI optical infrastructure. While some traders view the recent price decline as a significant dip-buying opportunity fueled by sector-wide volatility, others express frustration over the stock's sluggish movement and institutional pressure.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is trending as the community reacts to the company reaching a key milestone in its Phase 3 APPROACH trial ahead of schedule, with investors maintaining optimism for a Q4 topline data readout. Sentiment is further bolstered by the closing of a recent financing round and ongoing optimism regarding the broader psychedelic sector's regulatory and M&A landscape.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is trending amid high volatility as traders debate the sustainability of the AI semiconductor rally, with many dismissing concerns over AI development slowdowns as temporary "FUD" while others express caution regarding potential market corrections. The sentiment remains heavily polarized between those buying the dip for long-term growth and others positioning for further downside driven by macroeconomic pressures like rising oil prices and interest rate expectations.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending as traders focus on the upcoming HARMONi-3 clinical trial readout and a November FDA decision for ivonescimab, which is being positioned as a potential competitor to Keytruda. While sentiment remains divided over the drug's clinical data and the company's financial runway, the community is closely monitoring significant insider buying and elevated short interest as indicators of a possible short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The community remains deeply divided, with a vocal bearish contingent labeling the stock a scam and highlighting risks of dilution and potential delisting, while a smaller group of bulls discusses potential short-squeeze opportunities and the company's diagnostic product supply deals.

Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement

Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement PR...

Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds

Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds PR Newswire LONDON, July 10, 2026 LONDON, July 10, 2026...

Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds

Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds PR Newswire LONDON, July 9, 2026 LONDON, July 9, 2026 /PRNewswire/ -- Virax...

12 Health Care Stocks Moving In Thursday's Intraday Session

Gainers

Virax Biolabs Group (NASDAQ:VRAX) shares rose 178.9% to $8.87 during Thursday's regular session. The market value of their outstanding shares is at $2.5 million.
Forte Biosciences (NASDAQ:FBRX) stock roseread more...

These Companies Just Dropped Major Growth Catalysts

A wave of corporate announcements, from international distribution agreements and manufacturing leadership appointments to expanding government contracts and enterprise AI initiatives, several companies confirm strengthening revenue opportunities and long-term execution. $BLIS, $VRAX, $ENVX, $RKTO, $SPCX, $TDTH

Virax Biolabs Lands Strategic Southeast Asia Distribution Deal, Opening the Door to Commercial Revenue Across Six Countries

Virax Biolabs (NASDAQ:VRAX) has taken a meaningful step from product development toward commercial execution by signing an exclusive multi-country commercial supply agreement with Fosun Diagnostics, one of Asia's largest diagnostics organizations. While still an emerging biotechnology company, Virax is now positioned to begin generating near-term revenue from its commercially available ImmuneSelect research-use product line while continuing to develop its flagship ViraxImmune diagnostic platform.

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers

Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's pre-market session. The company's market cap stands at $2.5 million.
Alnylam Pharmaceuticals (NASDAQ:ALNY) stockread more...

Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics

Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics PR Newswire LONDON, July 9, 2026 LONDON, July 9, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the...

Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation

Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation PR Newswire LONDON, June 24, 2026 LONDON, June 24, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that...

Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune in Long COVID and Related Post-Acute Infection Syndromes

Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune in Long COVID and Related Post-Acute Infection Syndromes Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune in Long COVID and Related Post-Acute Infection Syndromes PR Newswire LONDON, May 26, 2026 LONDON, May 26...

Virax Biolabs Group Ltd. is a holding company, which engages in the sale, distribution, and marketing of diagnostics test kits and med-tech and personal protective equipment products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The company was founded by James Foster and Cameron Shaw in 2013 and is headquartered in London, the United Kingdom.

Virax Biolabs Group Ltd - Ordinary Shares - Class A

Neutral Sentiment

50bps hike

25bps hike

No change

25bps cut

The Federal Reserve's September FOMC meeting concludes Wednesday, September 16, with a rate decision due at 2:00 PM ET, following Tuesday's CPI report that showed inflation still running above the Fed's 2% target. What do you think the Fed decides at this week's FOMC meeting? Vote and explain your reasoning in the comments.

The Fed&#39;s rate decision comes Wednesday at 2PM ET. What do you think happens?

Stocktwits

The Fed's rate decision comes Wednesday at 2PM ET. What do you think happens?

Current Price	$2.61
Prev Close	$2.67
Open	$2.59
Dividend Yield	0.00%
50-Day Moving Average	$3.12
Beta	0.95
Avg. Volume	959,508.04
PE Ratio	-0.15

52-Week High	$21.75
52-Week Low	$2.50
Market Capitalization	$2.13M
EPS (Annual)	-$12.64
Price to Book	0.20
Revenue Per Employee	$477.81

Feed

News

Sentiment

Fundamentals

Info

VRAX Fundamentals